Granules India’s US Packaging Facility Clears Second FDA Inspection With NAI Status

Granules India Limited ( (IN:GRANULES) ) has shared an announcement.

Granules India’s U.S. step-down subsidiary, Granules Consumer Health, LLC, has received an Establishment Inspection Report with a No Action Indicated status from the U.S. Food and Drug Administration for its packaging facility in Manassas, Virginia. The inspection, conducted in December 2025, was the site’s second consecutive FDA audit to conclude with zero observations, underscoring the company’s strong quality and regulatory standards at a key packaging and distribution hub for OTC and prescription products in the U.S.

More about Granules India Limited

Granules India Limited is a Hyderabad-based pharmaceutical company that manufactures and supplies active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosage forms. Through its U.S. subsidiaries, the company focuses on over-the-counter and prescription products, leveraging integrated manufacturing and packaging capabilities to serve the U.S. consumer health market.

Average Trading Volume: 39,520

Technical Sentiment Signal: Strong Buy

Current Market Cap: 139.4B INR

For a thorough assessment of GRANULES stock, go to TipRanks’ Stock Analysis page.